News | Antiplatelet and Anticoagulation Therapies | August 03, 2017

Abbott Initiates XIENCE Short DAPT Clinical Trial

Trial will evaluate amount of time patients at high risk of bleeding should receive blood thinning medicine after treatment with Xience coronary stent

Abbott Initiates XIENCE Short DAPT Clinical Trial

August 3, 2017 — Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use dual antiplatelet therapy (DAPT) after receiving a Xience everolimus-eluting coronary stent

The study, called XIENCE Short DAPT, will evaluate if three months of DAPT is non-inferior to the current standard of 12 months after implantation with a Xience stent for patients who are at high risk of bleeding. The study will enroll approximately 2,000 patients at 100 sites in the United States and Asia.

Blood thinning medicines are prescribed for patients after stent implantation to prevent stent thrombosis, but can increase the risk for bleeding complications, particularly for high-bleeding risk patients. Approximately 1 in 5 patients who receive stents today are considered at high risk of bleeding.

“Limiting the duration of blood thinning medicine from 12 months to three months is particularly important for people at higher risk of bleeding due to factors such as older age, anemia, and renal disease," said Roxana Mehran, M.D., FACC, FACP, FCCP, FESC, FAHA, FSCAI, professor of medicine and director of interventional cardiovascular research and clinical trials at the Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai School of Medicine and global principal investigator of the study. “The results of this study will help determine if doctors can safely reduce the amount of time that high bleeding-risk patients must take blood thinning medication after receiving a Xience stent to unblock coronary arteries.”

XIENCE Short DAPT is a prospective, multi-center, open label, single-arm, non-randomized study. The primary endpoint is non-inferior rates of myocardial infarction or death in high-bleeding risk patients. Secondary endpoints include evaluation of the extent and severity of bleeding rates, stent thrombosis, stroke, revascularization, myocardial infarction and death.

The Xience family of everolimus-eluting coronary stent systems are indicated for improving coronary luminal diameter in patients, including people with diabetes mellitus, de novo chronic total coronary occlusions, people with symptomatic heart disease due to de novo native coronary artery lesions for Xience V (length ≤ 28 mm), Xience Prime, Xience Xpedition and Xience Alpine (lengths ≤ 32 mm) with reference vessel diameters of ≥2.25 mm to ≤ 4.25 mm.

Xience was approved in the U.S. in 2008.

Read the related article "Meta-Analysis Compares Efficacy, Safety of S-DAPT Versus L-DAPT After DES Implantation."
 

For more information: www.abbott.com

Related Content

Videos | 3-D Printing| November 17, 2017
Dee Dee Wang, M.D., Director, Structural Heart Imaging at Henry Ford Hospital, Detroit, explains how her center uses
News | Antiplatelet and Anticoagulation Therapies| November 16, 2017
Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated with direct oral...
SPRINT Trial Data Support New AHA/ACC Hypertension Guidelines
News | Hypertension| November 16, 2017
Findings from a landmark study funded by the National Institutes of Health (NIH) support a key component of the new...
Videos | Stents Bifurcation| November 15, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Videos | TCT| November 15, 2017
DAIC Editor Dave Fornell shows some of the innovations displayed on the expo floor at the 2017 Transcatheter Cardiova
Videos | FFR Technologies| November 15, 2017
A discussion with William Fearon, M.D.
Philips Azurion Image-Guided Therapy Platform Improves Clinical Workflow for Interventional Procedures
News | Angiography| November 15, 2017
Philips announced the results of a comprehensive, independent, two-year study demonstrating the clinical workflow...
Videos | Heart Valve Technology| November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
Videos | Left Atrial Appendage (LAA) Occluders| November 14, 2017
Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospita
News | Heart Failure| November 13, 2017
November 10, 2017 — Moderna Therapeutics announced a new license and collaboration with AstraZeneca to co-develop and
Overlay Init